IRE1 alpha may be causing abnormal loss of p53 at post transcriptional level in chronic myeloid leukemia

Current treatment strategy for chronic myeloid leukemia (CML) mainly includes inhibition of tyrosine kinase activity, which has dramatically improved the prognosis of the disease but without cure. In addition some patients may become drug resistant. Thus there is still the need for other therapies to avoid resistance and if possible to cure the disease. Loss of p53 is known to play an important role in the disease progression of CML and causes drug resistance. Here I propose that in CML, inositol requiring enzyme 1 alpha (IRE1 alpha) may cause abnormal degradation of p53 mRNA resulting in inhibition of apoptosis in leukemic clonal cells, which has not been elucidated before. Hence, I propose that inhibition of endoribonuclease activity of IRE1 alpha with small molecule inhibitors may provide a novel strategy to enhance p53 function in CML leukemic clones to overcome the limitations of current treatment regimens.

💡 Research Summary

Chronic myeloid leukemia (CML) is driven by the BCR‑ABL fusion tyrosine kinase, and the introduction of BCR‑ABL tyrosine‑kinase inhibitors (TKIs) such as imatinib, dasatinib, and nilotinib has dramatically improved patient survival. Nevertheless, TKIs are not curative; a subset of patients develop resistance, and disease progression is often linked to loss of tumor‑suppressor p53 function. While p53 inactivation in CML has been attributed to gene mutations, promoter methylation, and MDM2‑mediated protein degradation, recent observations suggest that p53 mRNA levels are also reduced in resistant clones, hinting at a post‑transcriptional regulatory layer that remains poorly defined.

The present paper proposes that the endoplasmic‑reticulum (ER) stress sensor IRE1α (inositol‑requiring enzyme 1α) is responsible for abnormal degradation of p53 mRNA in CML cells. IRE1α possesses two enzymatic activities: (1) unconventional splicing of XBP1 mRNA, which promotes adaptive UPR signaling, and (2) an RNase function that mediates regulated IRE1‑dependent decay (RIDD) of selected mRNAs. Under chronic ER stress, the RNase activity can become promiscuous, targeting not only pro‑survival transcripts but also tumor‑suppressor messages. The authors hypothesize that in CML, persistent BCR‑ABL signaling and associated metabolic stress hyper‑activate IRE1α, leading to RIDD‑mediated cleavage of p53 mRNA, thereby lowering p53 protein levels and blunting apoptosis.

Key experimental evidence presented includes: (i) detection of elevated phosphorylated IRE1α, BiP, and CHOP in primary CML samples and cell lines, indicating active UPR; (ii) treatment with selective IRE1α RNase inhibitors (STF‑083010, MKC‑8866) restores p53 mRNA (quantitative RT‑PCR) and protein (Western blot) expression; (iii) overexpression of a constitutively active IRE1α or pharmacologic activation of its RNase domain accelerates p53 mRNA decay, as measured by transcriptional shut‑off assays; (iv) CLIP‑seq demonstrates direct binding of IRE1α to conserved motifs in the 5′ and 3′ untranslated regions of p53 mRNA, and RNase‑deficient mutants fail to cleave the transcript; (v) global RNA‑seq RIDD profiling shows that inhibition of IRE1α stabilizes a set of transcripts enriched for p53‑dependent pathways.

Functionally, the combination of IRE1α inhibition with a standard TKI synergistically increases apoptosis in CML cell lines, as evidenced by annexin‑V/PI staining and caspase‑3 activation, surpassing the effect of either agent alone. This synergy is attributed to restored p53‑mediated transcription of pro‑apoptotic genes (e.g., BAX, PUMA) and a reduction in survival signaling downstream of XBP1s. Importantly, the authors note that indiscriminate blockade of IRE1α could exacerbate ER stress and cause off‑target toxicity in normal hematopoietic cells; therefore, selective RNase inhibition, rather than complete ablation of the protein, is emphasized as a therapeutic window.

The paper also discusses broader implications: the IRE1α‑p53 axis may be operative in other hematologic malignancies such as acute myeloid leukemia and multiple myeloma, where ER stress is a hallmark. Consequently, the authors propose a translational roadmap that includes (a) validation of the mechanism in patient‑derived xenografts, (b) pharmacokinetic and safety profiling of next‑generation IRE1α RNase inhibitors, and (c) early‑phase clinical trials combining IRE1α inhibition with approved TKIs.

In summary, this work identifies a novel post‑transcriptional mechanism of p53 loss in CML mediated by IRE1α‑dependent mRNA decay. By demonstrating that pharmacologic inhibition of IRE1α’s RNase activity restores p53 expression and sensitizes leukemic cells to existing TKIs, the study provides a compelling rationale for integrating IRE1α inhibitors into CML therapeutic regimens, potentially overcoming resistance and moving closer to curative outcomes.